{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2642323"],"location":["Japan"],"study_start_month":["6"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"The optimal cut off value of KRAS testing for the selection of unresectable colorectal cancer patients more likely to benefit from treatment with anti-EGFR in the first line setting.","description":"Primary outcome(s): Progression-free survival (PFS)","dates":{"creation":"2017-06-15"},"accession":"2642323","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000027108"]}}